{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:47:00Z","timestamp":1792262820519,"version":"4.4.0"},"reference-count":32,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) has several subtypes. The identification of markers associated with recurrence and poor prognosis in patients with TNBC is urgently needed. BRCAness is a set of traits in which BRCA1 dysfunction, arising from gene mutation, methylation, or deletion, results in DNA repair deficiency. In the current study, we evaluated the clinical significance and prognosis of BRCAness in a multicenter retrospective study. Ninety-four patients with TNBC treated with neoadjuvant chemotherapy were enrolled from three university hospitals for this retrospective study. BRCAness was evaluated in 94 core needle biopsy (CNB) specimens prior to neoadjuvant chemotherapy and 49 surgical specimens without pathological complete response (pCR). The samples were assessed using multiplex ligation-dependent probe amplification, and the amplicons were scored. Of the 94 patients, 51 had BRCAness in CNB specimens. There were no significant differences in pCR rates or recurrence between the BRCAness and non-BRCAness groups. Among surgical specimens, the BRCAness group had a significantly shorter recurrence-free survival and overall survival compared with the non-BRCAness group. The BRCAness of surgical specimens was found to be an important marker to predict prognosis in patients with TNBC after neoadjuvant chemotherapy. A clinical trial to assess the clinical impact of carboplatin with BRCAness is planned.<\/jats:p>","DOI":"10.3390\/diagnostics10020119","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T03:33:43Z","timestamp":1582515223000},"page":"119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-7439","authenticated-orcid":false,"given":"Yoshimasa","family":"Kosaka","sequence":"first","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6147-6828","authenticated-orcid":false,"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tanino","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishimiya","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3529-9706","authenticated-orcid":false,"given":"Mutsuko","family":"Yamamoto-Ibusuki","sequence":"additional","affiliation":[{"name":"Department of Molecular-Targeting Therapy for Breast Cancer, Kumamoto University Hospital, Kumamoto 860-8556, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hirota","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Showa University Koutou Toyosu Hospital, Koutou 135-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Iwase","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences Kumamoto University, Kumamoto 860-8556, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, Showa University School of Medicine, Shinagawa 142-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2065-7742","authenticated-orcid":false,"given":"Sadako","family":"Akashi-Tanaka","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, Showa University School of Medicine, Shinagawa 142-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2013.06.006","article-title":"Breast cancer classification by proteomic technologies: Current state of knowledge","volume":"40","author":"Lam","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"Jama"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0140-6736(11)61539-0","article-title":"Gene expression profiling in breast cancer: Classification, prognostication, and prediction","volume":"378","author":"Pusztai","year":"2011","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"Untch","year":"2012","journal-title":"J. Clin. Oncol.Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Timms","year":"2011","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3231","article-title":"Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer","volume":"14","author":"Byrski","year":"2012","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/bcr3049","article-title":"Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness","volume":"13","author":"Lips","year":"2011","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdq624","article-title":"An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients","volume":"22","author":"Vollebergh","year":"2011","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/bcr3655","article-title":"Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy","volume":"16","author":"Vollebergh","year":"2014","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tanino, H., Kosaka, Y., Nishimiya, H., Tanaka, Y., Minatani, N., Kikuchi, M., Shida, A., Waraya, M., Katoh, H., and Enomoto, T. (2016). BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165721"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1093\/annonc\/mdr621","article-title":"Clinical correlates of \u2018BRCAness\u2019 in triple-negative breast cancer of patients receiving adjuvant chemotherapy","volume":"23","author":"Oonk","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med Oncol. ESMO"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gross, E., van Tinteren, H., Li, Z., Raab, S., Meul, C., Avril, S., Laddach, N., Aubele, M., Propping, C., and Gkazepis, A. (2016). Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: A validation study. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2848-2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., and Redondo, A. (2018). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1814017"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2014.08.003","article-title":"BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy","volume":"15","author":"Watanabe","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mori, H., Kubo, M., Nishimura, R., Osako, T., Arima, N., Okumura, Y., Okido, M., Yamada, M., Kai, M., and Kishimoto, J. (2016). BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0167016"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Telli, M. (2014). Optimizing chemotherapy in triple-negative breast cancer: The role of platinum. Am. Soc. Clin. Oncol. Educ. Book. Am. Soc. Clin. Oncology. Annu. Meet., e37\u2013e42.","DOI":"10.14694\/EdBook_AM.2014.34.e37"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"212540","DOI":"10.7573\/dic.212540","article-title":"Advances in the use of PARP inhibitor therapy for breast cancer","volume":"7","author":"McCann","year":"2018","journal-title":"Drugs Context"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1200\/JCO.2016.72.1340","article-title":"Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women\u2019s Cancers: A Dose-Escalation, Phase I Study","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Garutti, M., Pelizzari, G., Bartoletti, M., Malfatti, M.C., Gerratana, L., Tell, G., and Puglisi, F. (2019). Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143390"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ijc.31898","article-title":"BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy","volume":"144","author":"Mio","year":"2019","journal-title":"Int. J. Cancer"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/2\/119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:59:54Z","timestamp":1760173194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/2\/119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["diagnostics10020119"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics10020119","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]}}}